Following a NASH crash, Conatus turns the keys over to regenerative med player
Six months after Conatus execs read last rites over their Novartis-partnered NASH program, they’ve handed the shell of what’s left to a regenerative med player for a reverse flip onto Nasdaq.
Conatus CEO Steven Mento put out a statement saying that the “merger” with Histogen was their best move. More likely it was their only one after the trial sputtered out after 4 straight clinical setbacks. Novartis had paid $50 million in cash to collaborate on that drug, surprising just about everyone in the field and temporarily offering a bright horizon to Conatus investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
